局灶性癫痫自身免疫病因筛查评分(ACES)的建立与验证
该前瞻性多中心队列研究纳入582例病因不明的成人局灶性癫痫患者,中位癫痫病程8年,随访1年,发现3.4%存在自身免疫性癫痫(AES)。基于多因素logistic回归建立ACES评分,外部验证C统计量为0.92,ACES≥2分检测AES的敏感性100%、特异性84.9%。
要点
- 病因不明的局灶性癫痫患者中,约3.4%存在自身免疫性病因。
- ACES评分≥2分筛查AES敏感性100%、特异性84.9%。
- 颞叶MRI高信号、自身免疫病、行为改变等是AES的危险因素。
核心结论
- 病因不明的局灶性癫痫患者中,特定临床特征提示自身免疫性癫痫,ACES评分( cutoff ≥2)可用于筛选需要抗体检测的患者。
研究设计与样本
- 前瞻性多中心队列研究,纳入2014年12月至2017年12月间病因不明的成人局灶性癫痫患者582例,随访1年。
- 通过多因素logistic回归确定支持自身免疫性癫痫的因素并建立ACES评分,进行外部验证(n=128)并计算C统计量。
主要发现
- 582例患者中20例(3.4%)存在自身免疫性癫痫,包括3例抗LGI1、3例抗CASPR2、1例抗NMDAR、13例抗GAD65(ELISA浓度>10,000 IU/ml)。
- AES的危险因素包括:颞叶MRI高信号(OR=255.3,95%CI=19.6-3332.2,p<0.0001)、自身免疫疾病(OR=13.31,95%CI=3.1-56.6,p=0.0005)、行为改变(OR=12.3,95%CI=3.2-49.9,p=0.0003)、自主神经症状(OR=13.3,95%CI=3.1-56.6,p=0.0005)、认知症状(OR=30.6,95%CI=2.4-382.7,p=0.009)、言语问题(OR=9.6,95%CI=2.0-46.7,p=0.005)。
- 内部验证C统计量为0.95,外部验证队列(n=128)C统计量为0.92。
关键数值与推荐
- ACES评分每项因素计1分,评分≥2分检测AES的敏感性为100%,特异性为84.9%。
临床怎么用
- 对于病因不明的局灶性癫痫患者,可依据ACES评分( cutoff ≥2)筛选需进行自身抗体检测的患者,以识别可能受益于免疫治疗者。
局限性
- 研究未明确报告局限性描述,故不列具体内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Diagnosing autoimmune encephalitis (AIE) is difficult in patients with less fulminant diseases such as epilepsy. However, recognition is important, as patients require immunotherapy. This study aims to identify antibodies in patients with focal epilepsy of unknown etiology, and to create a score to preselect patients requiring testing. METHODS: In this prospective, multicenter cohort study, adults with focal epilepsy of unknown etiology, without recognized AIE, were included, between December 2014 and December 2017, and followed for 1 year. Serum, and if available cerebrospinal fluid, were analyzed using different laboratory techniques. The ACES score was created using factors favoring an autoimmune etiology of seizures (AES), as determined by multivariate logistic regression. The model was externally validated and evaluated using the Concordance (C) statistic. RESULTS: We included 582 patients, with median epilepsy duration of 8 years (interquartile range = 2-18). Twenty patients (3.4%) had AES, of whom 3 had anti-leucine-rich glioma inactivated 1, 3 had anti-contactin-associated protein-like 2, 1 had anti-N-methyl-D-aspartate receptor, and 13 had anti-glutamic acid decarboxylase 65 (enzyme-linked immunosorbent assay concentrations >10,000IU/ml). Risk factors for AES were temporal magnetic resonance imaging hyperintensities (odds ratio [OR] = 255.3, 95% confidence interval [CI] = 19.6-3332.2, p < 0.0001), autoimmune diseases (OR = 13.31, 95% CI = 3.1-56.6, p = 0.0005), behavioral changes (OR 12.3, 95% CI = 3.2-49.9, p = 0.0003), autonomic symptoms (OR = 13.3, 95% CI = 3.1-56.6, p = 0.0005), cognitive symptoms (OR = 30.6, 95% CI = 2.4-382.7, p = 0.009), and speech problems (OR = 9.6, 95% CI = 2.0-46.7, p = 0.005). The internally validated C statistic was 0.95, and 0.92 in the validation cohort (n = 128). Assigning each factor 1 point, an antibodies contributing to focal epilepsy signs and symptoms (ACES) score ≥ 2 had a sensitivity of 100% to detect AES, and a specificity of 84.9%. INTERPRETATION: Specific signs point toward AES in focal epilepsy of unknown etiology. The ACES score (cutoff ≥ 2) is useful to select patients requiring antibody testing. ANN NEUROL 2021;89:698-710.
引用
- de Bruijn MAAM, Bastiaansen AEM, Mojzisova H, et al. Antibodies Contributing to Focal Epilepsy Signs and Symptoms Score. Ann Neurol. 2021. PMID: 33427313. doi:10.1002/ana.26013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。